Similar articles for PMID: 34930777

Year	Number of Results
1965	1
1977	1
1993	2
1994	1
1997	1
2000	1
2005	1
2007	1
2008	5
2010	5
2011	5
2012	7
2013	7
2014	6
2015	12
2016	8
2017	5
2018	9
2019	5
2020	12
2021	7
2024	0

1

Correction to "Performance of a universal prenatal screening program incorporating cell-free fetal DNA analysis in Ontario, Canada".

[No authors listed] [No authors listed] CMAJ. 2021 Dec 20;193(50):E1924. doi: 10.1503/cmaj.211995. CMAJ. 2021. PMID: 34930777 Free PMC article. No abstract available.

2

The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada.

Okun N, Teitelbaum M, Huang T, Dewa CS, Hoch JS. Okun N, et al. Prenat Diagn. 2014 Apr;34(4):350-6. doi: 10.1002/pd.4311. Epub 2014 Jan 28. Prenat Diagn. 2014. PMID: 24395030

3

Trends in the use of prenatal testing services for fetal aneuploidy in Ontario: a descriptive study.

Huang T, Dougan S, Walker M, Armour CM, Okun N. Huang T, et al. CMAJ Open. 2018 Oct 5;6(4):E436-E444. doi: 10.9778/cmajo.20180046. Print 2018 Oct-Dec. CMAJ Open. 2018. PMID: 30291139 Free PMC article.

4

Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis.

Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, Krahn M. Sander B, et al. PLoS Med. 2010 Apr 6;7(4):e1000256. doi: 10.1371/journal.pmed.1000256. PLoS Med. 2010. PMID: 20386727 Free PMC article.

5

Prenatal screening for fetal aneuploidy in singleton pregnancies.

Chitayat D, Langlois S, Douglas Wilson R; SOGC GENETICS COMMITTEE; CCMG PRENATAL DIAGNOSIS COMMITTEE. Chitayat D, et al. J Obstet Gynaecol Can. 2011 Jul;33(7):736-750. doi: 10.1016/S1701-2163(16)34961-1. J Obstet Gynaecol Can. 2011. PMID: 21749752

6

Universal screening for prenatal alcohol exposure: a progress report of a pilot study in the region of Grey Bruce, Ontario.

Zelner I, Shor S, Gareri J, Lynn H, Roukema H, Lum L, Eisinga K, Nulman I, Koren G. Zelner I, et al. Ther Drug Monit. 2010 Jun;32(3):305-10. doi: 10.1097/FTD.0b013e3181dca381. Ther Drug Monit. 2010. PMID: 20445484

7

The cost-effectiveness of targeted or universal screening for vasa praevia at 18-20 weeks of gestation in Ontario.

Cipriano LE, Barth WH Jr, Zaric GS. Cipriano LE, et al. BJOG. 2010 Aug;117(9):1108-18. doi: 10.1111/j.1471-0528.2010.02621.x. Epub 2010 Jun 18. BJOG. 2010. PMID: 20560948

8

Women's Experiences of Publicly Funded Non-Invasive Prenatal Testing in Ontario, Canada: Considerations for Health Technology Policy-Making.

Vanstone M, Yacoub K, Giacomini M, Hulan D, McDonald S. Vanstone M, et al. Qual Health Res. 2015 Aug;25(8):1069-84. doi: 10.1177/1049732315589745. Epub 2015 Jun 10. Qual Health Res. 2015. PMID: 26063605

9

Prenatal screening for trisomy 21: a comparative performance and cost analysis of different screening strategies.

Huang T, Gibbons C, Rashid S, Priston MK, Bedford HM, Mak-Tam E, Meschino WS. Huang T, et al. BMC Pregnancy Childbirth. 2020 Nov 23;20(1):713. doi: 10.1186/s12884-020-03394-w. BMC Pregnancy Childbirth. 2020. PMID: 33228595 Free PMC article.

10

Reducing Periconceptional Methylmercury Exposure: Cost-Utility Analysis for a Proposed Screening Program for Women Planning a Pregnancy in Ontario, Canada.

Gaskin J, Rennie C, Coyle D. Gaskin J, et al. Environ Health Perspect. 2015 Dec;123(12):1337-44. doi: 10.1289/ehp.1409034. Epub 2015 May 29. Environ Health Perspect. 2015. PMID: 26024213 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

90 results

Results by year